Johnson & Johnson to Buy Ollin Biosciences for 3.3B

Johnson & Johnson agreed to buy biotech Ollin Biosciences for up to 3.33 billion dollars. The deal expands its footprint in eye disease treatments with experimental drug OLN324. The acquisition is expected to close by the end of the year.

Xurve View
Insights:
The logo of Johnson&Johnson at the company's booth at the 9th China International Import Expo (CIIE) in Shanghai, China, November 6, 2026. REUTERS/Go Nakamura

JOHNSON & JOHNSON agreed to buy United States-based biotech Ollin Biosciences for up to $3.33 billion on Monday morning, expanding its footprint in eye disease therapies. The deal adds an experimental treatment for diabetic macular edema and wet age-related macular degeneration to the healthcare giant's portfolio. The acquisition helps strengthen a specialized segment where the company has held a limited presence despite its ACUVUE contact lens business.